Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OVACURE adoptive T-cell therapy in recurrent ovarian cancer
NL-OMON46179Phase 1Withdrawn
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GC101 TIL + pembrolizumab, interferon alfa, peginterferon alfa-2b, carboplatin, paclitaxel and 1 more in epithelial ovarian cancer (EOC) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Safety and toxicity, Dose-limiting toxicity and optimal interferon-alpha dose and 1 more. Planned start Nov 2016; status: withdrawn.
02
Drugs
GC101 TIL + pembrolizumabinterferon alfapeginterferon alfa-2bcarboplatinpaclitaxel
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NL-OMON46179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46179.